# ë°°ê²½ ìë£Œ: S4 í˜¸í¡ê¸° ì„¸ê·  ë³‘ì›ì²´ì˜ í•­ìƒì œ ì‹ ê·œ íƒ€ê²Ÿ

**ì„¸ì…˜**: S4 - New Therapeutic Targets for Antibiotics against Respiratory Bacterial Pathogens
**ì¼ì‹œ**: 2025ë…„ 10ì›” 27ì¼ (ì›”) 09:00-11:00
**ì¥ì†Œ**: Rm 301+302
**ì¤‘ìš”ë„**: â­â­â­â­â­ (95/100ì ) - **í•„ìˆ˜ ì°¸ì„!**

---

## ğŸ¯ ì„¸ì…˜ ê°œìš”

ì´ ì„¸ì…˜ì€ **ë‹¤ì œë‚´ì„± í˜¸í¡ê¸° ë³‘ì›ì²´ë¥¼ ê·¹ë³µí•  ì‹ ê·œ í•­ìƒì œ íƒ€ê²Ÿ**ì„ ë‹¤ë£¹ë‹ˆë‹¤. AMR ì—°êµ¬ìì—ê²Œ ê°€ì¥ ì¤‘ìš”í•œ ì„¸ì…˜ìœ¼ë¡œ, ìµœì‹  í•­ìƒì œ ê°œë°œ ì „ëµê³¼ ë³‘ì›ì²´ì˜ ìƒì¡´ ë©”ì»¤ë‹ˆì¦˜ì„ ë°°ìš¸ ìˆ˜ ìˆìŠµë‹ˆë‹¤.

### ì™œ ì´ ì„¸ì…˜ì´ ì¤‘ìš”í•œê°€?

- ğŸ”¬ **ì‹ ê·œ í•­ìƒì œ í´ë˜ìŠ¤**: ê¸°ì¡´ ë©”ì»¤ë‹ˆì¦˜ê³¼ ë‹¤ë¥¸ í˜ì‹ ì  íƒ€ê²Ÿ
- ğŸ¦  **ì£¼ìš” AMR ë³‘ì›ì²´**: MRSA, Pseudomonas, Mycobacteria ì§‘ì¤‘
- ğŸŒ **ë„ì‹¬ AMR ê°ì‹œ**: ì´ ë³‘ì›ì²´ë“¤ì€ ë„ì‹¬ í™˜ê²½ì—ì„œë„ í”íˆ ë°œê²¬ë¨
- ğŸ’Š **ì¦‰ì‹œ ì ìš© ê°€ëŠ¥**: ì§„ë‹¨ ë° ê°ì‹œ ì‹œìŠ¤í…œì— í™œìš© ê°€ëŠ¥í•œ ë°”ì´ì˜¤ë§ˆì»¤

---

## ğŸ“‹ ë°œí‘œë³„ ìƒì„¸ ë¶„ì„

### ğŸ”¹ ë°œí‘œ 1 (09:00-09:25)

**ì—°ì‚¬**: Wonsik Lee (ì´ì›ì‹)
**ì†Œì†**: Sungkyunkwan University, School of Pharmacy
**ì œëª©**: Environmental cues in different host niches shape the survival fitness of *Staphylococcus aureus*

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

Lee êµìˆ˜íŒ€ì€ **2025ë…„ Nature Communications**ì— íšê¸°ì ì¸ ì—°êµ¬ë¥¼ ë°œí‘œí–ˆìŠµë‹ˆë‹¤:

**í•µì‹¬ ë°œê²¬**:
- Transposon sequencing (Tn-Seq)ì„ ì‚¬ìš©í•˜ì—¬ MRSAê°€ **ë‹¤ì–‘í•œ ìˆ™ì£¼ í™˜ê²½**(ì„¸í¬ ë‚´, í˜ˆì•¡, ì¥ê¸°)ì—ì„œ ìƒì¡´í•˜ëŠ” ë° í•„ìš”í•œ ìœ ì „ìë¥¼ ì²´ê³„ì ìœ¼ë¡œ ë¶„ì„
- ì„¸í¬ ë‚´ vs. í˜ˆì•¡ í™˜ê²½ì—ì„œ ìƒì¡´ì— í•„ìš”í•œ **ìœ ì „ì ì„¸íŠ¸ê°€ ì™„ì „íˆ ë‹¤ë¦„** ë°œê²¬
- Harvard Medical School, MGHì™€ í˜‘ë ¥ ì—°êµ¬

**ì˜ˆìƒ ë°œí‘œ ë‚´ìš©**:
1. **Host niche-specific fitness determinants**
   - ì„¸í¬ ë‚´: ì²  íšë“, ìŠ¤íŠ¸ë ˆìŠ¤ ë°˜ì‘, ë©´ì—­ íšŒí”¼
   - í˜ˆì•¡: ì˜ì–‘ì†Œ ëŒ€ì‚¬, ë³´ì²´ ì €í•­ì„±
   - ì¥ê¸°: ë°”ì´ì˜¤í•„ë¦„ í˜•ì„±, ì§€ì†ì„±

2. **Environmental sensing mechanisms**
   - ì˜¨ë„, pH, ì‚°ì†Œ, ì˜ì–‘ì†Œ ë³€í™” ê°ì§€
   - Two-component systems (TCS) ì—­í• 
   - Quorum sensing

3. **Adaptive gene expression**
   - Niche-specific virulence factors
   - Metabolic reprogramming

#### ë‹¹ì‹ ì˜ ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ë„ì‹¬ AMR ê°ì‹œì— ì ìš©**:
- **ë‹¤ì–‘í•œ ë„ì‹¬ í™˜ê²½** (ëŒ€ê¸°, ë¬¼, í† ì–‘, í‘œë©´)ë„ ë‹¤ë¥¸ "niches"ë¡œ ë³¼ ìˆ˜ ìˆìŒ
- ê° í™˜ê²½ì—ì„œ S. aureusì˜ **ìƒì¡´ ë° í™•ì‚°ì— í•„ìš”í•œ ìœ ì „ì ë§ˆì»¤** íŒŒì•… ê°€ëŠ¥
- Tn-Seq ê¸°ë²•ì„ ë„ì‹¬ ìƒ˜í”Œì— ì ìš© â†’ **í™˜ê²½ë³„ AMR ê²°ì • ì¸ì ë°œê²¬**

**ë©”íƒ€ì§€ë…¸ë¯¹ìŠ¤ ì‘ìš©**:
- ë©”íƒ€ì§€ë…¸ë¯¹ ë°ì´í„°ì—ì„œ **environment-specific fitness genes** íƒìƒ‰
- íŠ¹ì • ìœ ì „ì ì¡´ì¬ = íŠ¹ì • í™˜ê²½ ì˜¤ì—¼ ì§€í‘œ

#### í•„ìˆ˜ ë°°ê²½ ì§€ì‹

**1. Transposon Sequencing (Tn-Seq)**
- **ì›ë¦¬**: ë¬´ì‘ìœ„ transposon insertion â†’ ê° mutantì˜ fitness ì¸¡ì •
- **ì¥ì **: genome-wideë¡œ essential genes ë™ì •
- **ë‹¨ì **: ì¡°ê±´ë³„ ë¶„ì„ í•„ìš” (ì‹œê°„/ë¹„ìš©)
- **ë„êµ¬**: TRANSIT, Tn-Seq Explorer

**2. Two-Component Systems (TCS)**
- Sensor kinase (í™˜ê²½ ê°ì§€) + Response regulator (ìœ ì „ì ì¡°ì ˆ)
- S. aureusì˜ ì£¼ìš” TCS:
  - **SaeRS**: ë©´ì—­ íšŒí”¼, virulence
  - **AgrCA**: quorum sensing
  - **WalKR**: ì„¸í¬ë²½ í•­ìƒì„±

**3. Host Niche Adaptation**
- **Intracellular niche**: phagosome escape, autophagy íšŒí”¼
- **Blood/serum**: complement resistance, iron scavenging (Isd system)
- **Biofilm**: eDNA, polysaccharides, persister cells

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ë‹¹ì‹ ì´ ë¬¼ì–´ë³¼ ì§ˆë¬¸**:
1. "Tn-Seqë¥¼ **í™˜ê²½ ìƒ˜í”Œ** (ë„ì‹¬ ëŒ€ê¸°/ë¬¼)ì— ì ìš©í•œ ì—°êµ¬ê°€ ìˆë‚˜ìš”? ì–´ë–¤ ê¸°ìˆ ì  ì±Œë¦°ì§€ê°€ ìˆì„ê¹Œìš”?"
2. "ê° niche-specific gene setì„ **ì§„ë‹¨ ë§ˆì»¤**ë¡œ í™œìš©í•  ìˆ˜ ìˆë‚˜ìš”? ì˜ˆë¥¼ ë“¤ì–´ í˜ˆì•¡ ê°ì—¼ vs. í”¼ë¶€ ê°ì—¼ êµ¬ë³„?"
3. "ë„ì‹¬ í™˜ê²½(ì˜ˆ: ì§€í•˜ì²  ê³µê¸°, ë³‘ì› í‘œë©´)ì—ì„œ S. aureusê°€ ë³´ì´ëŠ” **íŠ¹ìœ ì˜ ì ì‘ íŒ¨í„´**ì´ ìˆì„ê¹Œìš”?"

**í† ë¡  ì˜ˆìƒ**:
- Tn-Seq ì™¸ alternative methods (CRISPRi screening, RB-TnSeq)
- Clinical vs. environmental S. aureus ì°¨ì´
- í•­ìƒì œ ë‚´ì„± ìœ ì „ìì˜ niche-dependent expression

---

### ğŸ”¹ ë°œí‘œ 2 (09:25-09:50)

**ì—°ì‚¬**: Sung Jae Shin (ì‹ ì„±ì¬)
**ì†Œì†**: Yonsei University College of Medicine, Department of Microbiology
**ì œëª©**: Two major mycobacterial pathogens in South Korea: From distinct pathogenesis to therapeutic strategies

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

Shin êµìˆ˜ëŠ” **í•œêµ­ì˜ ê²°í•µ ë° NTM ì—°êµ¬ë¥¼ ì£¼ë„**í•˜ëŠ” ì—°êµ¬ìì…ë‹ˆë‹¤:

**ì£¼ìš” ì—°êµ¬ ì˜ì—­**:
1. **Mycobacterium tuberculosis (TB)**
   - ìˆ™ì£¼-ë³‘ì›ì²´ ìƒí˜¸ì‘ìš© ë° ë©´ì—­ íšŒí”¼
   - ì§€ì§ˆ ëŒ€ì‚¬ íƒ€ê²ŸíŒ… ì¹˜ë£Œ ì „ëµ
   - êµ­ê°€ ì—°êµ¬ì¬ë‹¨, í•œêµ­ë³´ê±´ì‚°ì—…ì§„í¥ì› ì§€ì›

2. **Nontuberculous Mycobacteria (NTM)**
   - *Mycobacterium avium* complex (MAC) - NTM íì§ˆí™˜ì˜ ì£¼ì›ì¸
   - ëŒ€ì‹ì„¸í¬ ê¸°ëŠ¥ ì¡°ì ˆì„ í†µí•œ ì„ ì²œ ë©´ì—­ ê°•í™”
   - NTM-KOREA ì½”í˜¸íŠ¸ ì—°êµ¬

**í•µì‹¬ ë°œê²¬**:
- TB ê°ì—¼ ì œì–´ë¥¼ ìœ„í•œ **ì§€ì§ˆ ëŒ€ì‚¬ íƒ€ê²ŸíŒ…** í˜ì‹ ì  ì „ëµ
- MACì— ëŒ€í•œ **ìˆ™ì£¼ ì„ ì²œ ì €í•­ì„± ê°•í™”** ì ‘ê·¼ë²•
- TB vs. NTMì˜ **ë³‘ì›ì„± ë©”ì»¤ë‹ˆì¦˜ ì°¨ì´**

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. í•œêµ­ì˜ ë‘ ì£¼ìš” ë§ˆì´ì½”ë°•í…Œë¦¬ì•„ ë³‘ì›ì²´**
- **M. tuberculosis**: ì—¬ì „íˆ ë†’ì€ ìœ ë³‘ë¥ , MDR-TB ë¬¸ì œ
- **M. avium complex**: ì¦ê°€í•˜ëŠ” ë°œë³‘ë¥ , ì¹˜ë£Œ ì–´ë ¤ì›€

**2. Distinct Pathogenesis (ë³‘ì›ì„± ì°¨ì´)**

| íŠ¹ì§• | TB | NTM (MAC) |
|------|----|----|
| **ê°ì—¼ ê²½ë¡œ** | ê³µê¸° ì „íŒŒ (ì¸ê°„â†’ì¸ê°„) | í™˜ê²½ ë…¸ì¶œ (ë¬¼, í† ì–‘) |
| **ìˆ™ì£¼ íƒ€ê²Ÿ** | ë©´ì—­ ì •ìƒì¸ | ë©´ì—­ì €í•˜ì, êµ¬ì¡°ì  íì§ˆí™˜ |
| **ì„±ì¥ ì†ë„** | ëŠë¦¼ (20ì‹œê°„) | ë§¤ìš° ëŠë¦¼ (48ì‹œê°„) |
| **ì¹˜ë£Œ ê¸°ê°„** | 6-9ê°œì›” | 12-18ê°œì›” ì´ìƒ |
| **ë©´ì—­ íšŒí”¼** | Granuloma í˜•ì„±, phagosome maturation ì–µì œ | Biofilm, ëŒ€ì‹ì„¸í¬ apoptosis ìœ ë„ |

**3. Therapeutic Strategies**

TB ì¹˜ë£Œ ì „ëµ:
- **ì§€ì§ˆ ëŒ€ì‚¬ íƒ€ê²ŸíŒ…**: mycolic acid í•©ì„± ì–µì œ
- ìˆ™ì£¼ ë©´ì—­ ì¡°ì ˆ
- Latent TB ì¬í™œì„±í™” ì˜ˆë°©

NTM ì¹˜ë£Œ ì „ëµ:
- ëŒ€ì‹ì„¸í¬ ê¸°ëŠ¥ ê°•í™” (cytokine modulation)
- í•­ìƒì œ ë³‘ìš© ìš”ë²• ìµœì í™”
- Biofilm íŒŒê´´

#### ë‹¹ì‹ ì˜ ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**ë„ì‹¬ í™˜ê²½ AMR ê°ì‹œ**:
- **NTMì€ í™˜ê²½ì„± ë³‘ì›ì²´** â†’ ë„ì‹¬ ë¬¼ ì‹œìŠ¤í…œ, ìƒ¤ì›Œí—¤ë“œ, ì—ì–´ë¡œì¡¸
- **ë©”íƒ€ì§€ë…¸ë¯¹ìŠ¤ë¡œ í™˜ê²½ NTM ê²€ì¶œ** ë° ì¢… ë™ì •
- NTM í•­ìƒì œ ë‚´ì„± ìœ ì „ì (erm, rrl mutations) ëª¨ë‹ˆí„°ë§

**í•­ìƒì œ ê°œë°œ ê´€ì **:
- Mycobacterial lipid biosynthesis = ë…íŠ¹í•œ íƒ€ê²Ÿ (ì¸ê°„ì— ì—†ìŒ)
- **Bedaquiline** (ATP synthase ì–µì œì œ) - TB ì¹˜ë£Œì˜ breakthrough
- í™˜ê²½ NTMì˜ intrinsic resistance mechanisms ì´í•´

#### í•„ìˆ˜ ë°°ê²½ ì§€ì‹

**1. Mycobacterial Cell Wall**
- **Unique structure**: peptidoglycan-arabinogalactan-mycolic acids
- **Mycolic acids**: ì´ˆì¥ì‡„ ì§€ë°©ì‚° (C60-C90)
- **Lipid barrier**: í•­ìƒì œ íˆ¬ê³¼ ì €í•­ì„±ì˜ ì£¼ì›ì¸

**2. Granuloma Formation**
- TBì˜ hallmark: ëŒ€ì‹ì„¸í¬, T cells, necrotic center
- **Paradox**: ë³‘ì›ì²´ ê²©ë¦¬ vs. ìƒì¡´ niche ì œê³µ
- Caseum (ì¹˜ì¦ˆ ê°™ì€ ê´´ì‚¬ ë¬¼ì§ˆ) - í•­ìƒì œ ì¹¨íˆ¬ ë¶ˆê°€

**3. NTM Environmental Reservoirs**
- **Biofilm í˜•ì„±**: ìˆ˜ë„ê´€, ìƒ¤ì›Œí—¤ë“œ
- **Chlorine resistance**: ì¼ë°˜ì ì¸ ì†Œë…ì œì— ë‚´ì„±
- **Aerosol transmission**: ìƒ¤ì›Œ, ê°€ìŠµê¸° â†’ í ê°ì—¼

**4. Drug Resistance Mechanisms**
- **Intrinsic**: ì„¸í¬ë²½ barrier, efflux pumps
- **Acquired**: rpoB (rifampin), katG (isoniazid), rrs (amikacin)
- **Extensively drug-resistant TB (XDR-TB)**: fluoroquinolones + injectable ì €í•­

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ë‹¹ì‹ ì´ ë¬¼ì–´ë³¼ ì§ˆë¬¸**:
1. "ë„ì‹¬ **ë¬¼ ì‹œìŠ¤í…œì—ì„œ NTMì˜ AMR í™•ì‚°**ì´ ìš°ë ¤ë˜ëŠ”ë°, í™˜ê²½ surveillance ì „ëµì€?"
2. "TBì™€ NTMì˜ **í•­ìƒì œ ë‚´ì„± ìœ ì „ìë¥¼ ë©”íƒ€ì§€ë…¸ë¯¹ìŠ¤ë¡œ ê²€ì¶œ**í•  ë•Œ ì–´ë–¤ ë§ˆì»¤ê°€ ê°€ì¥ ìœ ìš©í•œê°€ìš”?"
3. "ì§€ì§ˆ ëŒ€ì‚¬ íƒ€ê²ŸíŒ… ì•½ë¬¼ì´ **ë‹¤ë¥¸ ê·¸ëŒ ì–‘ì„±ê· **ì—ë„ ì ìš© ê°€ëŠ¥í•œê°€ìš”?"
4. "í•œêµ­ì˜ NTM ì¦ê°€ ì›ì¸ì´ **í™˜ê²½ ì˜¤ì—¼**ê³¼ ê´€ë ¨ ìˆë‹¤ëŠ” ì¦ê±°ê°€ ìˆë‚˜ìš”?"

**í† ë¡  ì˜ˆìƒ**:
- One Health approach: í™˜ê²½-ì„ìƒ NTM ì—°ê²°
- Rapid diagnostics (GeneXpert vs. NGS metagenomics)
- ì‹ ì•½ ê°œë°œ: bedaquiline, pretomanid, delamanid

---

### ğŸ”¹ ë°œí‘œ 3 (09:50-10:15) â­ **í•µì‹¬ ë°œí‘œ!**

**ì—°ì‚¬**: Jinki Yeom (ì—¼ì§„ê¸°)
**ì†Œì†**: Seoul National University, Department of Biomedical Sciences
**ì œëª©**: A new class of antibiotics overcomes multi-drug resistant bacteria by targeting outer layer glycolipid biosynthesis

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

Yeom êµìˆ˜ëŠ” **ì„¸ê· ì˜ ë©´ì—­ íšŒí”¼ ë° ìŠ¤íŠ¸ë ˆìŠ¤ ë°˜ì‘** ì „ë¬¸ê°€ì…ë‹ˆë‹¤:

**ì—°êµ¬ ì´ˆì **:
- ë³‘ì›ì„± ì„¸ê· ì´ ìˆ™ì£¼ ë©´ì—­ ë° í•­ìƒì œë¥¼ ì–´ë–»ê²Œ íšŒí”¼í•˜ëŠ”ê°€
- ì¥ê¸° ìƒì¡´ì„ ìœ„í•œ ìŠ¤íŠ¸ë ˆìŠ¤ ë°˜ì‘ ë©”ì»¤ë‹ˆì¦˜
- **Novel antibiotic targets** ë°œêµ´

**Glycolipid Biosynthesis íƒ€ê²ŸíŒ…**:
- **Outer membrane glycolipids** (íŠ¹íˆ LPS in Gram-negative)
- ì„¸í¬ í‘œë©´ capsular polysaccharides + glycolipid anchor
- **Why it works**: ì¸ê°„ì—ê²ŒëŠ” ì—†ëŠ” ê²½ë¡œ â†’ ì„ íƒì  ë…ì„±

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. ë‹¤ì œë‚´ì„±ê· ì˜ ë¬¸ì œ**
- **Carbapenem-resistant Enterobacteriaceae (CRE)**
- **Multidrug-resistant Acinetobacter baumannii**
- **Pseudomonas aeruginosa** (inherent resistance)

**2. Outer Layer Glycolipid Biosynthesisë€?**

**Gram-negative bacteria**:
```
Outer membrane
â”œâ”€ LPS (lipopolysaccharide)
â”‚  â”œâ”€ Lipid A (endotoxin)
â”‚  â”œâ”€ Core oligosaccharide
â”‚  â””â”€ O-antigen
â””â”€ Capsule (some species)
   â”œâ”€ Polysaccharide
   â””â”€ Glycolipid anchor (Kdo2-lipid A-like)
```

**í•µì‹¬ ê²½ë¡œ**:
- **Kdo (3-deoxy-D-manno-oct-2-ulosonic acid)** í•©ì„±
- **KdsB (CMP-Kdo synthetase)** - í•„ìˆ˜ íš¨ì†Œ
- **WaaA (Kdo transferase)** - LPS assembly

**3. ì‹ ê·œ í•­ìƒì œ ë©”ì»¤ë‹ˆì¦˜**

**íƒ€ê²Ÿ**: Glycolipid biosynthesis pathway enzymes
- **KdsB ì–µì œì œ**: LPS í•©ì„± ì°¨ë‹¨
- **WaaA ì–µì œì œ**: Outer membrane ë¶ˆì•ˆì •í™”

**ì˜ˆìƒ íš¨ê³¼**:
- Membrane permeability ì¦ê°€ â†’ ë‹¤ë¥¸ í•­ìƒì œì™€ ì‹œë„ˆì§€
- Immune recognition ì¦ê°€ (LPS ê²°ì†)
- Essential pathway â†’ broad-spectrum

**4. ì‹¤í—˜ ê²°ê³¼ (ì˜ˆìƒ)**
- **In vitro**: MIC (Minimum Inhibitory Concentration)
- **Resistance development**: ë‚®ì€ spontaneous mutation rate
- **Synergy**: Î²-lactams, aminoglycosidesì™€ ë³‘ìš©
- **In vivo**: Mouse infection model (survival rate)

#### ë‹¹ì‹ ì˜ ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**AMR ê°ì‹œ ê´€ì **:
- **Glycolipid synthesis genesë¥¼ ë©”íƒ€ì§€ë…¸ë¯¹ ë§ˆì»¤ë¡œ í™œìš©**
  - kdsA, kdsB, kdsC (Kdo í•©ì„±)
  - waaA, waaC, waaF (LPS assembly)
- Gene variants/mutations â†’ í•­ìƒì œ ê°ìˆ˜ì„± ì˜ˆì¸¡

**ë„ì‹¬ í™˜ê²½ ì ìš©**:
- Gram-negative pathogens (E. coli, Klebsiella, Acinetobacter) ë„ì‹¬ì—ì„œ í”í•¨
- ë³‘ì› íìˆ˜, í•˜ìˆ˜ â†’ í™˜ê²½ í™•ì‚°
- **Glycolipid biosynthesis gene abundance** ì¸¡ì • â†’ AMR burden í‰ê°€

**Drug discovery perspective**:
- Natural products targeting glycolipid synthesis
- High-throughput screening for inhibitors
- Structure-based drug design (KdsB crystal structure)

#### í•„ìˆ˜ ë°°ê²½ ì§€ì‹

**1. Lipopolysaccharide (LPS) Structure**
- **Lipid A**: 6ê°œ acyl chains, 2ê°œ glucosamine
  - TLR4 agonist (endotoxin activity)
  - Membrane anchor
- **Core oligosaccharide**: Kdo, heptose, hexose
  - Inner core (Kdo-Hep)
  - Outer core (hexoses)
- **O-antigen**: Repeating units (variable)
  - Serotype diversity
  - Immune evasion

**2. Kdo (3-deoxy-D-manno-oct-2-ulosonic acid)**
- **Unique 8-carbon sugar** (octose)
- **Essential** for most Gram-negative bacteria
  - E. coli: ìµœì†Œ 1ê°œ Kdo í•„ìš” (viability)
  - A. baumannii, P. aeruginosa: ë¹„ìŠ·
- **Biosynthesis**:
  ```
  Arabinose-5-P â†’ Kdo-8-P â†’ CMP-Kdo â†’ LPS
     (KdsD)         (KdsC, KdsB)      (WaaA)
  ```

**3. Why Glycolipid Biosynthesis = Good Target?**
- âœ… **Essential** for viability
- âœ… **Absent in humans** (no ortholog)
- âœ… **Conserved** across Gram-negatives
- âœ… **Surface-exposed** (accessibility)
- âš ï¸ **Challenge**: Penetration through outer membrane

**4. Existing Drugs Targeting LPS**
- **Colistin** (polymyxin E): LPS ê²°í•©, membrane disruption
  - Last-resort antibiotic
  - Nephrotoxicity, neurotoxicity
  - Resistance emerging (*mcr* genes)
- **Why new drugs needed?**: Colistin toxicity, resistance

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ë‹¹ì‹ ì´ ë¬¼ì–´ë³¼ ì§ˆë¬¸** (ìš°ì„ ìˆœìœ„ ë†’ìŒ!):
1. "**KdsB inhibitorì˜ êµ¬ì¡°**ë¥¼ ê³µê°œí•  ìˆ˜ ìˆë‚˜ìš”? Natural productì¸ê°€ìš”, syntheticì¸ê°€ìš”?"
2. "ë©”íƒ€ì§€ë…¸ë¯¹ ë°ì´í„°ì—ì„œ **kdsB/waaA ìœ ì „ì variants**ë¥¼ ì°¾ì•„ í•­ìƒì œ ê°ìˆ˜ì„±ì„ ì˜ˆì¸¡í•  ìˆ˜ ìˆì„ê¹Œìš”?"
3. "Gram-positive bacteria (S. aureus)ëŠ” LPSê°€ ì—†ëŠ”ë°, ìœ ì‚¬í•œ **glycolipid target**ì´ ìˆë‚˜ìš”? (Lipoteichoic acid?)"
4. "ë„ì‹¬ í™˜ê²½ ë¶„ë¦¬ì£¼(environmental isolates)ì—ì„œ ì´ ì•½ë¬¼ì˜ **efficacy**ë¥¼ í…ŒìŠ¤íŠ¸í–ˆë‚˜ìš”?"
5. "LPS í•©ì„± ì–µì œê°€ **endotoxin release**ë¥¼ ìœ ë°œí•˜ë‚˜ìš”? Septic shock ìš°ë ¤ëŠ”?"

**í† ë¡  ì˜ˆìƒ**:
- **Patent status**: ìƒì—…í™” ê°€ëŠ¥ì„±?
- **Clinical trials**: Phase I/II ì§„í–‰ ìƒí™©?
- **Resistance mechanisms**: Bypass pathways?
  - Kdo-independent LPS variants (rare)
  - Efflux pumps upregulation
- **Combination therapy**: Synergy with existing drugs?

**ë„¤íŠ¸ì›Œí‚¹ ì „ëµ**:
- â­ **ëª…í•¨ êµí™˜ í•„ìˆ˜!**
- Post-talk: "ë©”íƒ€ì§€ë…¸ë¯¹ìŠ¤ë¡œ glycolipid gene variants ë¶„ì„í•˜ëŠ”ë° ê´€ì‹¬ìˆìŠµë‹ˆë‹¤"
- Follow-up: "ë„ì‹œ í™˜ê²½ ìƒ˜í”Œë¡œ collaborative study ê°€ëŠ¥í• ê¹Œìš”?"

---

### ğŸ”¹ ë°œí‘œ 4 (10:15-10:40)

**ì—°ì‚¬**: Changhan Lee (ì´ì°½í•œ)
**ì†Œì†**: Ajou University, Department of Microbiology
**ì œëª©**: Acid-responsive proteostasis in *Pseudomonas aeruginosa*

#### ìµœê·¼ ì—°êµ¬ ë°°ê²½

Lee êµìˆ˜ëŠ” **ì„¸ê·  proteostasis (ë‹¨ë°±ì§ˆ í•­ìƒì„±)** ì „ë¬¸ê°€ì…ë‹ˆë‹¤:

**ì£¼ìš” ì—°êµ¬**:
- **FtsH proteases**: P. aeruginosaì˜ ë‹¨ë°±ì§ˆ í’ˆì§ˆ ê´€ë¦¬
- **Stress adaptation**: Heat-shock, acid stress
- **Growth arrest survival**: Proteaseì˜ ì—­í• 

**ê´€ë ¨ ë…¼ë¬¸**:
- **2019**: "Two FtsH Proteases Contribute to Fitness and Adaptation of Pseudomonas aeruginosa Clone C Strains" (Karolinska Institutet í˜‘ë ¥)

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. Pseudomonas aeruginosaì˜ ì„ìƒì  ì¤‘ìš”ì„±**
- **Opportunistic pathogen**: CF, immunocompromised
- **Intrinsic antibiotic resistance**:
  - Low outer membrane permeability
  - Efflux pumps (MexAB-OprM, MexXY)
  - Î²-lactamases (AmpC)
- **Biofilm formation**: Chronic infection

**2. Acid Stress in Host Environments**

P. aeruginosaê°€ ì§ë©´í•˜ëŠ” ì‚°ì„± í™˜ê²½:
- **Phagolysosome**: pH 4.5-5.0 (ëŒ€ì‹ì„¸í¬ ë‚´)
- **Cystic fibrosis sputum**: pH 5.5-6.5
- **Wound environment**: pH 5.5-6.5 (ì—¼ì¦)
- **Biofilm microenvironments**: pH gradients

**3. Proteostasis (ë‹¨ë°±ì§ˆ í•­ìƒì„±)**

**ì •ì˜**: ë‹¨ë°±ì§ˆ í•©ì„±, folding, trafficking, degradationì˜ ê· í˜•

**Acid stressì˜ ì˜í–¥**:
- Protein unfolding/misfolding ì¦ê°€
- Aggregation
- Oxidative damage

**Proteostasis network**:
```
Chaperones (Folding)
â”œâ”€ DnaK/DnaJ (Hsp70)
â”œâ”€ GroEL/GroES (Hsp60)
â””â”€ ClpB (Hsp100)

Proteases (Degradation)
â”œâ”€ FtsH (membrane-bound AAA+ protease)
â”œâ”€ Lon (cytoplasmic)
â”œâ”€ ClpXP/ClpAP
â””â”€ HslUV
```

**4. Acid-Responsive Proteostasis in P. aeruginosa**

**ì˜ˆìƒ ë©”ì»¤ë‹ˆì¦˜**:
- **pH sensing**: Two-component systems (e.g., PhoPQ)
- **Chaperone upregulation**: Heat-shock proteins
- **Protease activation**: FtsH, Lon
  - Misfolded protein ì œê±°
  - Stress response regulator ì¡°ì ˆ

**FtsH proteases**:
- **Membrane-anchored**: inner membrane proteins í’ˆì§ˆ ê´€ë¦¬
- **Targets**: Damaged membrane proteins, regulatory proteins
- **Fitness**: Growth, virulence, antibiotic tolerance

**5. ì¹˜ë£Œì  í•¨ì˜**

**Proteostasisë¥¼ íƒ€ê²ŸíŒ…**:
- **Protease inhibitors**: Proteostasis collapse â†’ cell death
- **Chaperone inhibitors**: Protein aggregation ìœ ë„
- **Synergy with antibiotics**: Stress response ì–µì œ â†’ ê°ìˆ˜ì„± ì¦ê°€

#### ë‹¹ì‹ ì˜ ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**AMR ê´€ì **:
- **Proteostasis = Stress tolerance** â†’ Antibiotic survival
- Protease mutants â†’ **Reduced fitness** in host
- **Biomarker**: FtsH, Lon expression levels â†’ AMR burden

**ë„ì‹¬ í™˜ê²½**:
- **Urban acid stress**: Acid rain, industrial pollution
- Proteostasis genes â†’ **Environmental adaptation markers**
- ë„ì‹¬ P. aeruginosa isolatesì˜ stress response profiling

**ë©”íƒ€ì§€ë…¸ë¯¹ìŠ¤**:
- Protease gene abundance (ftsH, lon, clpP)
- Chaperone gene variants
- Stress response transcription factors (rpoS, rpoE)

#### í•„ìˆ˜ ë°°ê²½ ì§€ì‹

**1. AAA+ Proteases**
- **ATPases Associated with diverse cellular Activities**
- ATP hydrolysis â†’ Protein unfolding â†’ Proteolysis
- **FtsH**:
  - Membrane-bound
  - ZnÂ²âº-dependent metalloprotease
  - Both protease + chaperone activity

**2. Acid Stress Response in Bacteria**
- **Periplasmic buffering**: Lysine decarboxylase
- **Cytoplasmic pH homeostasis**: Fâ‚Fâ‚€-ATPase (proton export)
- **Acid shock proteins**: Upregulated at low pH
- **Amino acid decarboxylases**: Consume Hâº

**3. Pseudomonas Stress Response**
- **Ïƒ factors** (Alternative sigma factors):
  - **RpoS (ÏƒË¢)**: Stationary phase, stress
  - **AlgU (Ïƒá´±)**: Envelope stress, alginate production
  - **RpoH (ÏƒÂ³Â²)**: Heat shock
- **Two-component systems**: PhoPQ, PmrAB (polymyxin resistance)

**4. Protein Quality Control**
- **Disaggregases**: ClpB, Hsp104 (aggregate dissolution)
- **Chaperones**: Prevent aggregation
- **Proteases**: Irreversibly damaged proteins ì œê±°
- **Degradation tags**: SsrA tag (tmRNA), N-end rule

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ë‹¹ì‹ ì´ ë¬¼ì–´ë³¼ ì§ˆë¬¸**:
1. "Acid stressê°€ **í•­ìƒì œ ë‚´ì„±**ì— ë¯¸ì¹˜ëŠ” ì˜í–¥ì€? Cross-resistance?"
2. "FtsH mutantsê°€ **biofilm í˜•ì„±**ì— ì–´ë–¤ ì˜í–¥ì„ ì£¼ë‚˜ìš”?"
3. "ë„ì‹¬ í™˜ê²½(pH ë³€ë™)ì—ì„œ P. aeruginosaì˜ **proteostasis gene expression**ì„ ë©”íƒ€ì „ì‚¬ì²´í•™ìœ¼ë¡œ ë¶„ì„í•  ìˆ˜ ìˆì„ê¹Œìš”?"
4. "Protease inhibitors + í•­ìƒì œ **combination therapy** ê°€ëŠ¥ì„±ì€?"

**í† ë¡  ì˜ˆìƒ**:
- Clinical isolates vs. environmental isolates ë¹„êµ
- FtsH as a drug target: Feasibility?
- Metatranscriptomics for stress response monitoring

---

### ğŸ”¹ ë°œí‘œ 5 (10:40-11:00)

**ì—°ì‚¬**: Junho Cho (ì¡°ì¤€í˜¸)
**ì†Œì†**: Yonsei University College of Medicine
**ì œëª©**: The strategy of MRSA against human antimicrobial peptides

#### ì—°êµ¬ ë°°ê²½

**Antimicrobial Peptides (AMPs)**:
- ì„ ì²œ ë©´ì—­ì˜ í•µì‹¬ ìš”ì†Œ
- Broad-spectrum activity
- Membrane disruption, immune modulation

**MRSAì˜ AMP ì €í•­ ì „ëµ**:
- Electrostatic repulsion (surface charge modification)
- Proteolytic degradation
- Efflux pumps
- Biofilm protection

#### ì˜ˆìƒ ë°œí‘œ ë‚´ìš©

**1. Human Antimicrobial Peptides**
- **Defensins**: Î±-defensins (neutrophils), Î²-defensins (epithelial)
- **Cathelicidins**: LL-37 (human cathelicidin)
- **Mechanism**: Membrane permeabilization, immunomodulation

**2. MRSA Resistance Mechanisms**

**Surface charge modification**:
- **D-alanylation of teichoic acids** (DltABCD operon)
  - Wall teichoic acid (WTA) + D-Ala â†’ Positive charge â†‘
  - Repels cationic AMPs
- **L-lysinylation of phosphatidylglycerol** (MprF)
  - PG (negative) â†’ Lys-PG (positive)
  - Membrane charge â†‘

**Proteolytic degradation**:
- **Aureolysin** (Aur): Metalloprotease
- **SspA/B**: Serine proteases (V8 protease)
- Cleave AMPs â†’ Inactivation

**Efflux pumps**:
- **Tet38**: Tetracycline + AMP efflux
- **MepA**: Multidrug efflux

**Biofilm**:
- Extracellular matrix: eDNA, proteins, polysaccharides
- AMP sequestration
- Reduced penetration

**3. Regulation**

**Two-component systems**:
- **GraRS (VraRS)**: Senses AMP stress â†’ dltABCD, mprF upregulation
- **ApsRS (VraFG)**: Similar function

**Quorum sensing**:
- **Agr system**: Regulates virulence factors, proteases
- AMP stress â†’ Agr activation â†’ Protease production

**4. ì¹˜ë£Œì  í•¨ì˜**

**AMP resistanceë¥¼ ê·¹ë³µí•˜ëŠ” ì „ëµ**:
- **Peptidomimetics**: Protease-resistant AMPs
- **Synergy**: AMPs + í•­ìƒì œ
- **Resistance inhibitors**:
  - DltA inhibitors: Surface charge restoration
  - MprF inhibitors
- **Engineered AMPs**: Non-cationic, novel mechanisms

#### ë‹¹ì‹ ì˜ ì—°êµ¬ì™€ì˜ ì—°ê²°ì 

**AMR ê°ì‹œ**:
- **AMP resistance genes**ë¥¼ ë©”íƒ€ì§€ë…¸ë¯¹ ë§ˆì»¤ë¡œ í™œìš©
  - dltABCD, mprF, graRS
  - Protease genes (aur, sspA/B)
- Gene abundance â†’ AMP resistance burden

**ë„ì‹¬ í™˜ê²½**:
- ì‚¬ëŒ-í™˜ê²½ ì ‘ì´‰ ë§ì€ ê³³ (ëŒ€ì¤‘êµí†µ, ë³‘ì›)
- AMP-resistant MRSA í™•ì‚°
- Environmental AMP exposure (e.g., disinfectants)

**í•­ìƒì œ ê°œë°œ**:
- Novel AMPs targeting Gram-negatives
- AMP + antibiotic combinations

#### í•„ìˆ˜ ë°°ê²½ ì§€ì‹

**1. Teichoic Acids**
- **Wall teichoic acid (WTA)**: Peptidoglycanì— ê³µìœ  ê²°í•©
- **Lipoteichoic acid (LTA)**: ë§‰ì— anchoring
- **Functions**:
  - Cell division, autolysis regulation
  - Cation binding (MgÂ²âº, CaÂ²âº)
  - Immune recognition (TLR2 ligand)
  - **D-alanylation**: Positive charge â†’ AMP resistance

**2. MprF (Multiple peptide resistance factor)**
- **Bifunctional enzyme**:
  - Synthase: PG + Lys â†’ Lys-PG
  - Flippase: Lys-PGë¥¼ outer leafletë¡œ ì´ë™
- **Result**: Membrane surface charge â†‘ â†’ Cationic AMP repulsion

**3. Agr Quorum Sensing**
- **AIP (autoinducing peptide)**: Quorum sensing signal
- **AgrC/AgrA**: TCS
- **RNAIII**: Effector, virulence gene regulator
- **Phenotypes**:
  - Agr+ (high): Toxin, protease â†‘, biofilm â†“
  - Agr- (low): Biofilm â†‘, toxin â†“

**4. AMP Mechanism of Action**
- **Barrel-stave model**: Peptides form pore
- **Carpet model**: Membrane disruption (detergent-like)
- **Toroidal pore**: Lipids + peptides form pore
- **Non-lytic**: Intracellular targets (DNA, RNA, protein synthesis)

#### ì˜ˆìƒ ì§ˆë¬¸ & í† ë¡  í¬ì¸íŠ¸

**ë‹¹ì‹ ì´ ë¬¼ì–´ë³¼ ì§ˆë¬¸**:
1. "ë„ì‹¬ í™˜ê²½ì—ì„œ **AMP-resistant MRSAì˜ prevalence**ëŠ”? Clinical isolatesì™€ ì°¨ì´?"
2. "**D-alanylation inhibitors** ê°œë°œ í˜„í™©? Clinical trials?"
3. "ë©”íƒ€ì§€ë…¸ë¯¹ìŠ¤ë¡œ **dltA/mprF variants**ë¥¼ ê²€ì¶œí•´ AMP ê°ìˆ˜ì„± ì˜ˆì¸¡ ê°€ëŠ¥í•œê°€ìš”?"
4. "Engineered AMPs (e.g., LL-37 analogs)ì˜ **environmental stability**ëŠ”?"

**í† ë¡  ì˜ˆìƒ**:
- AMP as therapeutic agents: Challenges?
- Synergy: AMPs + Î²-lactams/vancomycin
- Probiotic AMPs: Nisin, lantibiotics

---

## ğŸ§  ì„¸ì…˜ ì „ì²´ í•µì‹¬ ê°œë… ì •ë¦¬

### í•„ìˆ˜ ì•”ê¸° ì‚¬í•­

**1. ì£¼ìš” Pathogen-Target ë§¤ì¹­**
| Pathogen | Main Target | Mechanism | Potential Drug |
|----------|-------------|-----------|----------------|
| MRSA | AMP resistance (DltA, MprF) | Surface charge â†‘ | DltA inhibitors |
| P. aeruginosa | Proteostasis (FtsH) | Stress tolerance | Protease inhibitors |
| MDR Gram (-) | Glycolipid biosynthesis (KdsB) | LPS synthesis | KdsB inhibitors |
| Mycobacteria | Lipid metabolism | Cell wall synthesis | Lipid pathway inhibitors |

**2. ê³µí†µ í…Œë§ˆ: Stress Response â†’ Antibiotic Tolerance**
```
Environmental Stress
 â†“
Proteostasis Network Activation
 â†“
Chaperones â†‘ + Proteases â†‘
 â†“
Misfolded Proteins Removed
 â†“
Survival + Antibiotic Tolerance
```

**3. Novel Drug Classes**
- **Glycolipid biosynthesis inhibitors** (Yeom)
- **Protease inhibitors** (Lee)
- **DltA inhibitors** (Cho)
- **Lipid metabolism modulators** (Shin)

### ë©”íƒ€ì§€ë…¸ë¯¹ìŠ¤ AMR Markers

ì´ ì„¸ì…˜ì—ì„œ ë°°ìš´ **ìœ ì „ì ë§ˆì»¤ë“¤ì„ ë„ì‹¬ AMR ê°ì‹œì— í™œìš©**:

```yaml
MRSA Markers:
  - mecA (MRSA)
  - dltABCD (AMP resistance)
  - mprF (AMP resistance)
  - graRS (Regulation)

P. aeruginosa Markers:
  - ftsH (Proteostasis)
  - lon, clpP (Proteases)
  - rpoS (Stress response)
  - mexAB-oprM (Efflux)

Gram-negative MDR:
  - kdsA/B/C (Glycolipid synthesis)
  - waaA/C/F (LPS assembly)
  - blaKPC, blaNDM (Carbapenemases)

Mycobacteria:
  - rpoB (Rifampin resistance)
  - katG (Isoniazid resistance)
  - erm, rrl (Macrolide resistance, NTM)
```

---

## ğŸ“š ì‚¬ì „ ì½ê¸° ìë£Œ (ìš°ì„ ìˆœìœ„)

### í•„ìˆ˜ (Must Read)

1. **Wonsik Lee (2025)** - Nature Communications
   - "Environmental cues in different host niches shape the survival fitness of Staphylococcus aureus"
   - ì½ê¸°: ìµœì†Œ Abstract, Figures

2. **Glycolipid Biosynthesis Review**
   - "Targeting LPS biosynthesis and transport in gram-negative bacteria in the era of multi-drug resistance" (2023, PMC9922520)

3. **AMP Resistance**
   - "Antimicrobial Peptides: The Game-Changer in the Epic Battle Against Multidrug-Resistant Bacteria" (2024, PMC11597525)

### ì¶”ì²œ (Highly Recommended)

4. **Mycobacteria Therapeutics**
   - "Understanding Metabolic Regulation Between Host and Pathogens" (Sung Jae Shin, 2021)

5. **Pseudomonas Proteostasis**
   - "Heat-shock proteases promote survival of Pseudomonas aeruginosa during growth arrest" (2020, PMC7049150)

### ì„ íƒ (Optional but Useful)

6. **NTM Environmental Reservoirs**
   - "Leveraging Advances in Tuberculosis Diagnosis and Treatment to Address Nontuberculous Mycobacterial Disease" (2016)

---

## ğŸ¤ ì¤€ë¹„í•  ì§ˆë¬¸ ë¦¬ìŠ¤íŠ¸ (ìš°ì„ ìˆœìœ„)

### Top 3 Questions (ê¼­ ë¬¼ì–´ë³´ê¸°!)

1. **[Yeom]** "KdsB inhibitorì˜ í™”í•™ êµ¬ì¡°ì™€ ì‘ìš© ë©”ì»¤ë‹ˆì¦˜ì„ ì¢€ ë” ìì„¸íˆ ì•Œ ìˆ˜ ìˆì„ê¹Œìš”? íŠ¹íˆ **ë©”íƒ€ì§€ë…¸ë¯¹ ë°ì´í„°ì—ì„œ kdsB variantsë¡œ í•­ìƒì œ ê°ìˆ˜ì„± ì˜ˆì¸¡**ì´ ê°€ëŠ¥í•œì§€ ê¶ê¸ˆí•©ë‹ˆë‹¤."

2. **[Lee (Wonsik)]** "Tn-Seq ê¸°ë²•ì„ **ë„ì‹¬ í™˜ê²½ ìƒ˜í”Œ**(ì˜ˆ: ëŒ€ê¸°, í•˜ìˆ˜)ì— ì ìš©í•´ environment-specific AMR determinantsë¥¼ ì°¾ì„ ìˆ˜ ìˆì„ê¹Œìš”? ê¸°ìˆ ì  ì±Œë¦°ì§€ëŠ”?"

3. **[Shin]** "NTMì´ ë„ì‹¬ **ë¬¼ ì‹œìŠ¤í…œ**ì—ì„œ ì¦ê°€í•˜ê³  ìˆëŠ”ë°, í™˜ê²½ surveillanceì™€ clinical surveillanceë¥¼ ì—°ê²°í•˜ëŠ” **ë©”íƒ€ì§€ë…¸ë¯¹ìŠ¤ ê¸°ë°˜ ì „ëµ**ì€ ë¬´ì—‡ì¼ê¹Œìš”?"

### Backup Questions (ì‹œê°„ í—ˆìš©ì‹œ)

4. **[Lee (Changhan)]** "Acid stress responseì™€ antibiotic toleranceì˜ ê´€ê³„ë¥¼ ë„ì‹¬ í™˜ê²½(pH ë³€ë™)ì—ì„œ **metatranscriptomics**ë¡œ ëª¨ë‹ˆí„°ë§í•  ìˆ˜ ìˆì„ê¹Œìš”?"

5. **[Cho]** "AMP resistance genes (dltA, mprF)ë¥¼ ë„ì‹¬ AMR burdenì˜ **ë©”íƒ€ì§€ë…¸ë¯¹ biomarker**ë¡œ í™œìš©í•œ ì—°êµ¬ê°€ ìˆë‚˜ìš”?"

---

## ğŸ¤ ë„¤íŠ¸ì›Œí‚¹ ì „ëµ

### ìš°ì„ ìˆœìœ„ 1: Jinki Yeom (ì—¼ì§„ê¸°) - SNU

**Why?**
- ì‹ ê·œ í•­ìƒì œ í´ë˜ìŠ¤ ê°œë°œ â†’ ê°€ì¥ í˜ì‹ ì 
- AMR ì—°êµ¬ì™€ ì§ê²°
- ì„œìš¸ëŒ€ (ì§€ë¦¬ì ìœ¼ë¡œ ê°€ê¹Œì›€)

**ì ‘ê·¼ ì „ëµ**:
1. ë°œí‘œ ì§í›„ ì§ˆë¬¸ (KdsB inhibitor + metagenomics)
2. Poster session/receptionì—ì„œ follow-up
3. ëª…í•¨ êµí™˜: "ë©”íƒ€ì§€ë…¸ë¯¹ìŠ¤ë¡œ glycolipid biosynthesis genes ë¶„ì„í•˜ê³  ìˆìŠµë‹ˆë‹¤"
4. Email follow-up (1ì£¼ ë‚´): "ë„ì‹¬ í™˜ê²½ ìƒ˜í”Œë¡œ collaborative study ê´€ì‹¬ìˆìŠµë‹ˆë‹¤"

### ìš°ì„ ìˆœìœ„ 2: Wonsik Lee (ì´ì›ì‹) - SKKU

**Why?**
- Tn-Seq ì „ë¬¸ê°€ â†’ ê¸°ë²• í•™ìŠµ ê¸°íšŒ
- Nature Communications ì €ì
- Environment-host niche ì—°ê²° = ë„ì‹¬ AMRê³¼ ê´€ë ¨

**ì ‘ê·¼ ì „ëµ**:
1. Tn-Seq ê¸°ë²• ì ìš©ì— ëŒ€í•´ í† ë¡ 
2. í™˜ê²½ ìƒ˜í”Œ fitness gene profiling ì•„ì´ë””ì–´ ì œì‹œ
3. Potential collaboration: Urban vs. clinical S. aureus

### ìš°ì„ ìˆœìœ„ 3: Sung Jae Shin (ì‹ ì„±ì¬) - Yonsei

**Why?**
- Mycobacteria ì „ë¬¸ê°€ (TB + NTM)
- í™˜ê²½ NTM = ë„ì‹¬ ë¬¼ ì‹œìŠ¤í…œ ë¬¸ì œ
- One Health approach

**ì ‘ê·¼ ì „ëµ**:
1. NTM environmental surveillanceì— ëŒ€í•´ ì§ˆë¬¸
2. ë©”íƒ€ì§€ë…¸ë¯¹ìŠ¤ë¡œ NTM AMR ê²€ì¶œ
3. ì„œìš¸/ìˆ˜ë„ê¶Œ ë¬¼ ì‹œìŠ¤í…œ collaborative study

---

## âš¡ ì„¸ì…˜ ë‹¹ì¼ ì²´í¬ë¦¬ìŠ¤íŠ¸

### ì‚¬ì „ ì¤€ë¹„ (ì „ë‚ ê¹Œì§€)
- [ ] Wonsik Lee (2025) ë…¼ë¬¸ ì½ê¸°
- [ ] Glycolipid biosynthesis review ì½ê¸°
- [ ] ì—°ì‚¬ë³„ ìµœê·¼ ë…¼ë¬¸ abstract ì½ê¸°
- [ ] ì§ˆë¬¸ ë¦¬ìŠ¤íŠ¸ ì •ë¦¬ (ì¸ì‡„ ë˜ëŠ” ë…¸íŠ¸)
- [ ] ëª…í•¨ ì¤€ë¹„ (í•œê¸€/ì˜ë¬¸ ê° 10ì¥)

### ì„¸ì…˜ ë‹¹ì¼ (10/27 ì•„ì¹¨)
- [ ] ë…¸íŠ¸ë¶/íƒœë¸”ë¦¿ + ì¶©ì „ê¸°
- [ ] ëª…í•¨ + ë³¼íœ
- [ ] ì§ˆë¬¸ ë©”ëª¨ì§€
- [ ] Rm 301+302 ìœ„ì¹˜ í™•ì¸ (ë¯¸ë¦¬ ê°€ë³´ê¸°)
- [ ] 09:00 **10ë¶„ ì „ ë„ì°©** (ì•ìë¦¬ ì„ ì )

### ì„¸ì…˜ ì¤‘
- [ ] ê° ë°œí‘œë§ˆë‹¤ í•µì‹¬ í¬ì¸íŠ¸ ë©”ëª¨
- [ ] Slide ì‚¬ì§„ ì°ê¸° (í—ˆìš©ë˜ë©´)
- [ ] ì‹¤ì‹œê°„ ì§ˆë¬¸ ë©”ëª¨
- [ ] ì—°ì‚¬ ì—°ë½ì²˜ ìˆ˜ì§‘

### ì„¸ì…˜ ì§í›„
- [ ] ì—°ì‚¬ 3ëª…ê³¼ ì§ì ‘ ëŒ€í™” (Yeom, Lee W, Shin)
- [ ] ëª…í•¨ êµí™˜ + ì¦‰ì„ ë©”ëª¨ (ë’·ë©´ì—)
- [ ] Poster session ì‹œê°„ ì•½ì†
- [ ] ì ì‹¬ ì•½ì† ê°€ëŠ¥í•˜ë©´ ì œì•ˆ

---

## ğŸ”— ë‹¤ë¥¸ ì„¸ì…˜ê³¼ì˜ ì—°ê²°

**S8 (AMR ì§„ë‹¨)ê³¼ ì—°ê³„**:
- S4ì—ì„œ ë°°ìš´ **novel targets** â†’ S8ì˜ **diagnostic biomarkers**ë¡œ í™œìš©
- Glycolipid biosynthesis genes â†’ PCR/LAMP primers ë””ìì¸
- AMP resistance genes â†’ Rapid detection assays

**S12 (í™˜ê²½ ë©”íƒ€ì§€ë…¸ë¯¹ìŠ¤)ê³¼ ì—°ê³„**:
- S4ì˜ **environmental adaptation genes** (Wonsik Lee) â†’ S12ì˜ **single-cell genomics**ë¡œ ë¶„ì„
- ë„ì‹¬ í™˜ê²½ì—ì„œ fitness genes íƒìƒ‰

---

**ì˜ˆìƒ í•™ìŠµ ì„±ê³¼**:
ì´ ì„¸ì…˜ í›„ ë‹¹ì‹ ì€:
âœ… 4ê°€ì§€ novel antibiotic targets ì´í•´
âœ… ë©”íƒ€ì§€ë…¸ë¯¹ìŠ¤ AMR marker set í™•ë³´ (20+ genes)
âœ… 3ëª… ì´ìƒì˜ í•µì‹¬ ì—°êµ¬ìì™€ ë„¤íŠ¸ì›Œí‚¹
âœ… ë„ì‹¬ AMR ê°ì‹œ ì—°êµ¬ ì•„ì´ë””ì–´ 3ê°œ ì´ìƒ ë„ì¶œ

**ë§ˆì§€ë§‰ íŒ**: ğŸ¤ ì§ˆë¬¸ì€ **êµ¬ì²´ì ì´ê³  ì§§ê²Œ**! "In urban environments..." ë¡œ ì‹œì‘í•˜ë©´ ë‹¹ì‹ ì˜ ì—°êµ¬ì™€ ì—°ê²°í•˜ê¸° ì‰½ìŠµë‹ˆë‹¤.
